Published in Oncotarget on November 15, 2014
Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology (2015) 0.77
Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy. J Immunol Res (2016) 0.75
The Expression of HMGB1 in Bone Marrow MSCs Is Upregulated by Hypoxia with Regulatory Effects on the Apoptosis and Adhesion. Biomed Res Int (2016) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer (2003) 10.88
Neuroblastoma. Lancet (2007) 10.61
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med (1995) 9.02
Recent advances in neuroblastoma. N Engl J Med (2010) 7.86
Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol (1999) 7.66
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol (2010) 5.65
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res (2005) 5.33
Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell (2011) 4.79
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A (2011) 3.45
Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res (2008) 2.67
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell (2012) 2.34
Antiangiogenic therapy and tumor progression. Cancer Cell (2004) 2.20
Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology (2010) 1.96
Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets (2010) 1.91
High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res (2000) 1.85
C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol (2009) 1.85
Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci U S A (2012) 1.83
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol (2005) 1.75
A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene (2006) 1.62
Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol (2007) 1.62
Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol (1998) 1.59
Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol (2012) 1.58
EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther (2011) 1.54
Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res (2012) 1.52
Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J Biol Chem (2002) 1.46
The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol (2007) 1.45
Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta (2010) 1.38
Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene (2012) 1.37
Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett (2006) 1.34
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) (2013) 1.31
Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology (2011) 1.31
Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum (2008) 1.27
Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PLoS One (2012) 1.25
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int J Oncol (2001) 1.18
Tumorigenesis: Twist1 links EMT to self-renewal. Nat Cell Biol (2010) 1.17
Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol (2011) 1.16
Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol (1999) 1.10
Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett (1993) 1.02
IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2. PLoS One (2011) 1.02
Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Res (2011) 1.02
Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition. Cancer Sci (2012) 0.97
Combination of N-(4-hydroxyphenyl) retinamide and apigenin suppressed starvation-induced autophagy and promoted apoptosis in malignant neuroblastoma cells. Neurosci Lett (2011) 0.94
Neural stem/progenitor cells express 20 tenascin C isoforms that are differentially regulated by Pax6. J Biol Chem (2007) 0.92
Human tenascin gene. Structure of the 5'-region, identification, and characterization of the transcription regulatory sequences. J Biol Chem (1995) 0.89
High-mobility group box protein 1: a novel mediator of inflammatory-induced renal epithelial-mesenchymal transition. Am J Nephrol (2010) 0.88
Hematological cancer in 2011: New therapeutic targets and treatment strategies. Nat Rev Clin Oncol (2012) 0.88
HIF2A and IGF2 expression correlates in human neuroblastoma cells and normal immature sympathetic neuroblasts. Neoplasia (2013) 0.87
In vivo evolution of tumor-derived endothelial cells. PLoS One (2012) 0.86
Carbon dioxide, hypoxia and low pH lead to overexpression of c-myc and HMGB-1 oncogenes in neuroblastoma cells. Eur J Pediatr Surg (2009) 0.82
Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-gamma. Br J Cancer (2006) 0.82
A complement receptor C5a antagonist regulates epithelial to mesenchymal transition and crystallin expression after lens cataract surgery in mice. Mol Vis (2011) 0.82
Mind the gap: potential for rebounds during antiangiogenic treatment breaks. Clin Cancer Res (2012) 0.81
Intratumoral diversity of telomere length in individual neuroblastoma tumors. Oncotarget (2015) 0.82
Interleukin-30 Promotes Breast Cancer Growth and Progression. Cancer Res (2016) 0.75